JP2017515837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515837A5 JP2017515837A5 JP2016567370A JP2016567370A JP2017515837A5 JP 2017515837 A5 JP2017515837 A5 JP 2017515837A5 JP 2016567370 A JP2016567370 A JP 2016567370A JP 2016567370 A JP2016567370 A JP 2016567370A JP 2017515837 A5 JP2017515837 A5 JP 2017515837A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antagonist
- taa
- agonist
- immunogenic combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000005557 antagonist Substances 0.000 claims description 134
- 238000000034 method Methods 0.000 claims description 125
- 239000000556 agonist Substances 0.000 claims description 121
- 206010028980 Neoplasm Diseases 0.000 claims description 48
- 239000000427 antigen Substances 0.000 claims description 39
- 102000036639 antigens Human genes 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 201000011510 cancer Diseases 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 28
- 238000009472 formulation Methods 0.000 claims description 26
- 241000700629 Orthopoxvirus Species 0.000 claims description 23
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 22
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 21
- 102100034256 Mucin-1 Human genes 0.000 claims description 21
- 229940124060 PD-1 antagonist Drugs 0.000 claims description 19
- 241000700663 Avipoxvirus Species 0.000 claims description 16
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 16
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 16
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 13
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 13
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 12
- 102000000763 Survivin Human genes 0.000 claims description 10
- 108010002687 Survivin Proteins 0.000 claims description 10
- 241000700618 Vaccinia virus Species 0.000 claims description 10
- 241000700662 Fowlpox virus Species 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 229940032310 PROSTVAC vaccine Drugs 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- 101100262328 Mus musculus Dct gene Proteins 0.000 claims description 6
- 101100154912 Mus musculus Tyrp1 gene Proteins 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 claims description 3
- 102000013563 Acid Phosphatase Human genes 0.000 claims description 3
- 108010051457 Acid Phosphatase Proteins 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 230000006798 recombination Effects 0.000 claims description 2
- 238000005215 recombination Methods 0.000 claims description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
- 208000007089 vaccinia Diseases 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims 25
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 238000011275 oncology therapy Methods 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 107
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 107
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 12
- 230000037396 body weight Effects 0.000 description 10
- 229940022511 therapeutic cancer vaccine Drugs 0.000 description 9
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 7
- 101000796203 Homo sapiens L-dopachrome tautomerase Proteins 0.000 description 6
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 6
- 102000017578 LAG3 Human genes 0.000 description 6
- 101150030213 Lag3 gene Proteins 0.000 description 6
- 229940123803 TIM3 antagonist Drugs 0.000 description 5
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992788P | 2014-05-13 | 2014-05-13 | |
| US61/992,788 | 2014-05-13 | ||
| PCT/US2015/029855 WO2015175334A2 (en) | 2014-05-13 | 2015-05-08 | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515837A JP2017515837A (ja) | 2017-06-15 |
| JP2017515837A5 true JP2017515837A5 (enExample) | 2018-06-14 |
| JP6747981B2 JP6747981B2 (ja) | 2020-08-26 |
Family
ID=53499070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567370A Active JP6747981B2 (ja) | 2014-05-13 | 2015-05-08 | 腫瘍抗原発現組換えポックスウイルス及び免疫チェックポイント分子アンタゴニストまたはアゴニストを用いた癌治療のための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170266270A1 (enExample) |
| EP (1) | EP3142690B1 (enExample) |
| JP (1) | JP6747981B2 (enExample) |
| KR (1) | KR102499737B1 (enExample) |
| CN (1) | CN106456747A (enExample) |
| AU (1) | AU2015259510B2 (enExample) |
| CA (1) | CA2946418C (enExample) |
| DK (1) | DK3142690T3 (enExample) |
| ES (1) | ES2913236T3 (enExample) |
| IL (1) | IL248507B (enExample) |
| NZ (1) | NZ725459A (enExample) |
| RU (1) | RU2724433C2 (enExample) |
| WO (1) | WO2015175334A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10441654B2 (en) | 2014-01-24 | 2019-10-15 | Children's Hospital Of Eastern Ontario Research Institute Inc. | SMC combination therapy for the treatment of cancer |
| KR102504758B1 (ko) * | 2014-07-16 | 2023-02-28 | 트랜스진 | 종양 세포 붕괴성 바이러스와 면역 체크포인트 조절제의 배합물 |
| CN107949397A (zh) * | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | 免疫治疗疫苗和抗体组合治疗 |
| CA2977660A1 (en) | 2015-02-25 | 2016-09-15 | Memorial Sloan-Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| US10548930B2 (en) | 2015-04-17 | 2020-02-04 | Memorial Sloan Kettering Cancer Center | Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors |
| AU2016294440B2 (en) | 2015-07-13 | 2022-10-13 | Cytomx Therapeutics, Inc | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of use thereof |
| SG11201807051VA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy |
| BR112018016948A2 (pt) | 2016-02-25 | 2019-01-08 | Memorial Sloan Kettering Cancer Center | mva recombinante ou mva¿e3l que expressa flt3l humano e uso do mesmo como agente imunoterapêutico contra tumores sólidos |
| MX2018011306A (es) * | 2016-03-18 | 2019-08-16 | Nantcell Inc | Vector multimodal para infeccion de celulas dentriticas. |
| EP3225253A1 (en) * | 2016-04-01 | 2017-10-04 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Cancer therapy with an oncolytic virus combined with a checkpoint inhibitor |
| CN107281474A (zh) * | 2016-04-11 | 2017-10-24 | 中国科学院上海巴斯德研究所 | 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物 |
| RS65007B1 (sr) | 2016-06-02 | 2024-01-31 | Ultimovacs Asa | Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kancera |
| KR20190088480A (ko) * | 2016-11-02 | 2019-07-26 | 조운스 테라퓨틱스, 인크. | Pd-1에 대한 항체 및 그의 용도 |
| KR200486872Y1 (ko) | 2016-11-16 | 2018-07-10 | 김영선 | 가변형 조립식 책상 |
| EP3621646A4 (en) | 2017-05-12 | 2021-06-02 | Memorial Sloan Kettering Cancer Center | USEFUL VACCINE VIRUS MUTANTS FOR ANTI-CANCER IMMUNOTHERAPY |
| JP7334124B2 (ja) | 2017-06-21 | 2023-08-28 | トランジェーヌ | 個別化ワクチン |
| WO2019038388A1 (en) | 2017-08-24 | 2019-02-28 | Bavarian Nordic A/S | POLYTHERAPY FOR THE TREATMENT OF CANCER BY INTRAVENOUS ADMINISTRATION OF RECOMBINANT MVA AND ANTIBODY |
| CN111556760A (zh) * | 2017-11-06 | 2020-08-18 | 纪念斯隆-凯特林癌症中心 | 作为疫苗免疫佐剂的热灭活的牛痘病毒 |
| US20190367568A1 (en) * | 2018-02-05 | 2019-12-05 | Nantbio, Inc. | Calreticulin and fusion proteins |
| TWI816603B (zh) * | 2018-04-23 | 2023-09-21 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
| US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
| MX2021003013A (es) | 2018-09-15 | 2021-08-11 | Memorial Sloan Kettering Cancer Center | Poxvirus recombinantes para inmunoterapia contra cáncer. |
| WO2020104531A1 (en) | 2018-11-20 | 2020-05-28 | Bavarian Nordic A/S | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| US20220152168A1 (en) * | 2019-03-20 | 2022-05-19 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Sequential heterologous boost oncolytic viral immunotherapy |
| JP7732977B2 (ja) | 2019-09-20 | 2025-09-02 | トランスジーン | Ｈｐｖポリペプチドおよびｉｌ－２をコードするポックスウイルスと抗ｐｄ－ｌ１抗体の組合せ |
| CA3161800A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| MX2022005664A (es) * | 2019-11-20 | 2022-09-07 | Bavarian Nordic As | Virus de vaccinia ankara modificados (mva) recombinantes para administración intratumoral y/o intravenosa para tratamiento de cáncer. |
| CN114929268A (zh) * | 2019-11-20 | 2022-08-19 | 巴法里安诺迪克有限公司 | 4-1bbl辅助的重组修饰的安卡拉痘苗病毒(mva)的医疗用途 |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1119354A (en) * | 1914-01-05 | 1914-12-01 | Adelbert Armstrong | Broom-holder. |
| US1391972A (en) * | 1920-08-05 | 1921-09-27 | American Cotton Oil Company | Method and apparatus for molding soap |
| KR101498834B1 (ko) * | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
-
2015
- 2015-05-08 NZ NZ725459A patent/NZ725459A/en unknown
- 2015-05-08 KR KR1020167030977A patent/KR102499737B1/ko active Active
- 2015-05-08 CN CN201580034007.8A patent/CN106456747A/zh active Pending
- 2015-05-08 CA CA2946418A patent/CA2946418C/en active Active
- 2015-05-08 DK DK15733563.9T patent/DK3142690T3/da active
- 2015-05-08 ES ES15733563T patent/ES2913236T3/es active Active
- 2015-05-08 AU AU2015259510A patent/AU2015259510B2/en active Active
- 2015-05-08 IL IL248507A patent/IL248507B/en unknown
- 2015-05-08 EP EP15733563.9A patent/EP3142690B1/en active Active
- 2015-05-08 US US15/310,405 patent/US20170266270A1/en not_active Abandoned
- 2015-05-08 JP JP2016567370A patent/JP6747981B2/ja active Active
- 2015-05-08 RU RU2016148311A patent/RU2724433C2/ru active
- 2015-05-08 WO PCT/US2015/029855 patent/WO2015175334A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017515837A5 (enExample) | ||
| RU2016148311A (ru) | Комбинированная терапия для лечения рака с помощью рекомбинантного поксвируса, экспрессирующего опухолевый антиген, и антагониста или агониста молекулы иммунной контрольной точки | |
| JP2017515841A5 (enExample) | ||
| JP2016537417A5 (enExample) | ||
| RU2016122035A (ru) | Комбинированное лекарственное средство для лечения рака с использованием поксвируса, экспрессирующего опухолевый антиген, и антагониста и/или агониста ингибитора имунной контрольной точки | |
| JP7368305B2 (ja) | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ－３に対するモノクローナル抗体を用いた癌治療のための併用療法 | |
| Yang et al. | DNA vaccine for cancer immunotherapy | |
| Tobias et al. | Vaccination against Her-2/neu, with focus on peptide-based vaccines | |
| EP2980101A1 (en) | Vaccine comprising an n-terminal, pest sequence comprising fragment of listeriolysin (llo) protein fused to a her-2 antigen | |
| Pierini et al. | Trial watch: DNA-based vaccines for oncological indications | |
| JP2019517508A5 (enExample) | ||
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| Chang et al. | Vaccinating against cancer: getting to prime time | |
| US20210213060A1 (en) | Compositioins for inducing an immune response | |
| Kraynyak et al. | Tapping the potential of DNA delivery with electroporation for cancer immunotherapy | |
| JPWO2020104531A5 (enExample) | ||
| PH12020500194A1 (en) | Malaria vaccine | |
| JPWO2021099586A5 (enExample) | ||
| Friedlaender et al. | A new generation of vaccines in the age of immunotherapy | |
| JPWO2021074648A5 (enExample) | ||
| NZ759184B2 (en) | Methods of treating bladder cancer | |
| Kim et al. | Phase 2 trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, in patients with metastatic, refractory renal cell carcinoma (RCC) | |
| JP2017531699A5 (enExample) | ||
| NZ759184A (en) | Methods of treating bladder cancer | |
| US20180028630A1 (en) | Compositions and methods for therapeutic anti-cancer vaccination |